Heartburn | YesPress

Browse all tags

ceo2909 saas2415 ai1731 fintech1456 founder1251 b2b1079 b2b saas888 san francisco823 co-founder816 san-francisco799 y combinator769 startup734 machine learning665 enterprise software625 stanford603 series a590 venture capital577 biotech543 cybersecurity535 healthtech479 new york startup469 ai agents452 enterprise-software447 generative ai437 digital health434 agentic ai393 silicon-valley389 d2c386 silicon valley381 ecommerce379 machine-learning373 startup founder360 california351 entrepreneur350 new york347 edtech343 venture-capital340 climate tech328 newsletter321 mit302 proptech302 robotics294 y-combinator281 san francisco startup278 enterprise ai276 series b273 developer tools264 computer vision255 oncology252 open-source247 series-a244 harvard242 supply chain241 sustainability240 iot232 enterprise229 biotechnology224 compliance224 workflow automation223 telehealth217 founder ceo216 healthcare213 insurtech212 developer-tools211 blockchain210 devops208 medical devices206 series-b206 logistics199 forbes 30 under 30194 llm193 uc berkeley189 author188 generative-ai188 clean energy187 deep tech187 web3185 cloud184 a16z183 drug discovery182 b2c176 life sciences176 artificial intelligence175 no-code175 manufacturing174 payments170 general partner169 healthcare ai169 crm168 serial entrepreneur167 seed funding164 open source162 automation160 podcast160 hardware159 digital transformation158 unicorn158 marketplace152 predictive analytics152 infrastructure151

Often tagged with

pharmaceuticals1 biopharmaceutical1 gastrointestinal1 gerd1 vonoprazan1 voquezna1 p-cab1 potassium-competitive acid blocker1 acid suppression1 h. pylori1 erosive esophagitis1 drug development1 fda approval1 biotech1

Tagged: heartburn

1 result

Sort

Health · Enterprise

Phathom Pharmaceuticals

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company built around vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB) it licensed from Takeda in 2019 for the U.S., Europe and Canada. Its lead product, VOQUEZNA, won FDA approval in late 2023 - the first major innovation in U.S. GERD treatment in over 30 years - and is sold for non-erosive and erosive GERD plus H. pylori infection via its DUAL PAK and TRIPLE PAK regimens. The company reached $175.1 million in net revenue in 2025 and expects operating profitability in 2026.

pharmaceuticals · biopharmaceuticalRead →